Aggarwal R, et al. - Researchers assessed the effectiveness, safety, tolerability and steroid-sparing impact of repository corticotropin injection (RCI), in an open-label clinical trial, in refractory adult polymyositis (PM) and dermatomyositis (DM). As per the data, in 70% of patients, treatment with RCI was effective, safe and tolerable. This treatment led to a steroid dose reduction in patients with adult myositis refractory to glucocorticoid and traditional immunosuppressive drugs. Experts did not note any significant weight gain or an increase in hemoglobin A1c or cushingoid features.